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Abstract 
Background: As low HDL cholesterol levels are a risk factor for cardiovascular disease, raising HDL 
cholesterol substantially by inhibiting or modulating cholesteryl ester transfer protein (CETP) may be 
useful in coronary artery disease.  The first CETP inhibitor that went into clinical trial, torcetrapib, 
was shown to increase the levels of HDL cholesterol, but it also increased cardiovascular outcomes, 
probably due to an increase in blood pressure and aldosterone secretion, by an off-target 
mechanism/s. 
Objective/methods: Dalcetrapib is a new CETP modulator that increases the levels of HDL 
cholesterol, but does not increase blood pressure or aldosterone secretion.  The objective was to 
evaluate a paper describing the effects of dalcetrapib on carotid and aortic wall thickness in subjects 
with, or at high risk, of coronary artery disease; the dal-PLAQUE study. 
Results: dal-PLAQUE showed that dalcetrapib reduced the progression of atherosclerosis and may 
also reduce the vascular inflammation associated with this, in subjects with, or with high risk of, 
coronary heart disease, who were already taking statins.   
Conclusions: These results suggest that modulating CETP with dalcetrapib may be a beneficial 
mechanism in cardiovascular disease.  The results of the dal-HEART series, which includes dal-
PLAQUE 1 and 2, and dal-OUTCOMES, when complete, will provide more definitive information 
about the benefit, or not, of dalcetrapib in coronary artery disease. 
 
Key words CETP, coronary artery disease, dalcetrapib, dal-HEART, dal-PLAQUE, HDL cholesterol, 
statins, torcetrapib 
  
3 
 
1. Introduction 
Although the low-density lipoprotein (LDL) cholesterol-lowering statins reduce the mortality and 
morbidity associated with coronary artery disease, considerable mortality and morbidity remains in 
this disease.  Low high-density lipoprotein (HDL) cholesterol levels (< 0.91 mmol/L) are also an 
independent risk factor for premature coronary disease.  Epidemiology studies suggest that an 
increase in HDL-cholesterol levels of 0.03 mmol/L is associated with a 2-4% reduction in the risk of 
cardiovascular disease [1]. 
The fibrates are commonly used to increase the levels of HDL cholesterol in clinical practice, despite 
only having a modest effect on the levels.  For example, gemfibrozil causes a 6% increase in HDL 
cholesterol, had no effect on LDL cholesterol, and decreased triglycerides by 31%, in subjects with 
coronary artery disease and low LDL cholesterol, and this led to a decrease in non-fatal myocardial 
infarction or death from coronary heart disease [2] and stroke [3].  In subjects with type 2 diabetes, 
fenofibrate increased HDL cholesterol by 8%, decreased LDL cholesterol by 6%, and decreased 
triglycerides by 30%, and this led to a reduction in the angiographic progression of coronary artery 
disease [4].  As these benefits with fibrates are accompanied by rather modest increases in HDL 
cholesterol, other approaches to increase the levels of HDL cholesterol have been considered.  One 
of these is inhibition of cholesteryl ester transfer protein (CETP), which can be achieved with the 
‘cetrapib’ drugs: torcetrapib, anacetrapib, dalcetrapib, and evacetrapib. 
Torcetrapib was the first of the CETP inhibitors to go into Phase III clinical trial in the ILLUMINATE 
(Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events) trial 
[5].  ILLUMINATE was stopped prematurely in 2006, when torcetrapib was shown to increase 
cardiovascular events in subjects with a history of cardiovascular disease [5].  In addition to 
increasing the levels of HDL cholesterol in ILLUMINATE, torcetrapib was shown to increase blood 
pressure, aldosterone levels, and prolong the QT interval, and it was postulated that these effects 
might underlie the increase in cardiovascular disease [5].  
Three large blood-vessel imaging studies also failed to demonstrate any benefit with torcetrapib.  
Thus, torcetrapib had no effect on coronary artery atheroma in ILLUSTRATE (Investigation of Lipid 
Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP 
Inhibition and HDL cholesterol) [6] or carotid artery intima-media thickness in the RADIANCE (Rating 
Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor) trials [7, 8]. 
After torcetrapib’s failure, it was hypothesised that CETP inhibitors, as a class, increased HDL 
cholesterol and were proinflammatory, or proatherogenic, and may, thereby, increase coronary 
morbidity and mortality [9].  The dal-HEART program (the Dalcetrapib, HDL Evaluation, 
Atherosclerosis and Reverse Cholesterol Transport) program has been established to determine the 
safety and efficacy of dalcetrapib, which was initially characterised as a CETP inhibitor.  One of these 
studies, dal-PLAQUE, which was set up to test the effect of dalcetrapib on atherosclerosis, has 
recently been reported, and is discussed in Section 3 [10].  In Section 2, there is a brief review of the 
findings with dalcetrapib prior to dal-PLAQUE in Section 2. 
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2. The dalcetrapib story so far 
Dalcetrapib (JTT-705) was discovered by the Japan Tobacco Company, and considered a small 
molecule inhibitor of CETP, then licensed to Roche (RO4607381) for clinical development in 2004 
(reviewed in [11]).  In 2002, dalcetrapib (300 – 900 mg) for 4 weeks was shown to inhibit CETP 
activity by 37%, increase HDL cholesterol by 34%, decrease LDL cholesterol by 7%, and had no effect 
on triglycerides in 198 subjects with mild hyperlipidemia [12]. 
After torcetrapib failed in 2006, there was a controversy as to whether the increased morbidity and 
mortality observed, which were probably due to blood pressure rises, were secondary to CETP 
inhibitor, and therefore a class effect.  This was checked with dalcetrapib by comparing it with 
torcetrapib in spontaneously hypertensive rats, and, whereas torcetrapib caused a sustained 
increase in blood pressure, dalcetrapib did not [13].  Also, torcetrapib increased renin-angiotensin-
aldosterone systems mRNA in the adrenal glands and aortas of the rats, whereas dalcetrapib did not 
[13], and thus is unlikely to increase aldosterone levels.     
Subsequently, the efficacy and safety of dalcetrapib has been determined in more subjects and over 
longer periods.  A pooled analysis of 838 subjects four 4-week, and one 12-week trial, showed that 
dalcetrapib increased HDL cholesterol by 36% [14].  For the 600 mg dose of dalcetrapib, adverse 
effects were similar to the placebo group, but for the higher dose of dalcetrapib 900 mg, there were 
more adverse effects with dalcetrapib than in the placebo group, but the excess was predominantly 
mild transient gastrointestinal adverse effects [14].  The ability of dalcetrapib to increase the levels 
of HDL cholesterol was maintained over 48 weeks in subjects with coronary heart disease or risk, 
without any effect on blood pressure or aldosterone secretion [15].  Dalcetrapib also has no effect 
on the QT interval in healthy subjects following multiple dosing [16]. 
3. dal-PLAQUE: methods and results 
The methods and results of the Phase 2b double-blind, randomised, placebo-controlled study 
showing dalcetrapib reduced the increase in area of vessels [10], is summarised here.  
The study enrolled subjects with known coronary heart disease or at high risk of coronary artery 
disease, which was diabetes or a 10-year risk of coronary heart disease events > 20% by Framingham 
Risk scoring.  Subjects also had to have vessel wall thickening, measured as the carotid or aortic 
arterial wall (target) to background (blood ratio) of 1.6 or higher, identified by 18-F-
fluorodeoxyglucose positron emission tomography/computed tomography (18F-FCG uptake on 
PET/CT).  Subjects also had to have triglycerides of ≤ 4.5 mmol/L, and statin treatment to give a level 
of LDL cholesterol of < 2.6 mmol/L.  Subjects were not enrolled if they were taking other agents to 
increase HDL cholesterol, such as the fibrates or nicotinic acid.  Subjects were also excluded if they 
had uncontrolled blood pressure or diabetes, a recent vascular event, or poor kidney function. 
The subjects enrolled had a mean age of ~ 63 years, and were predominantly White (~93%) and male 
(~82%).  About 85% had a history of coronary artery disease, and many (73%) had hypertension, and 
some (30%) had diabetes.  Most of the subjects were taking statins (~86%), and were stabilised on 
these to have a LDL cholesterol level of < 2.6 mmol, and the baseline LDL cholesterol level was 1.9 
mmol/L.  Subjects (130) were randomised to placebo or dalcetrapib 600 mg.  Over 24 months, the 
rates of discontinuation and of adverse effects were similar in the placebo and dalcetrapib groups. 
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The co-primary imaging endpoint with MRI was structural changes in the wall of the carotid artery.  
The baseline mean total vessel area in the placebo group was 60.2 mm2, and this increased to 67.5 
mm2 in the placebo group, whereas there was little change in the dalcetrapib group (baseline, 62.8 
mm2:  dalcetrapib, 61.4 mm2) over 24 months.  The absolute change between placebo and the 
dalcetrapib group was a loss of 4.01 mm2, which was significantly different (p = 0.04).  However, 
despite this significant reduction in total vessel area with dalcetrapib, compared to placebo over 24 
months, there was no significant difference between the wall area or thickness with placebo and 
dalcetrapib. 
The co-primary PET/CT endpoint assessed vascular inflammation measured by 18F-FDG uptake, 
mainly into the aorta, measured by arterial wall (target) to background (blood) ratio.  This ratio was 
1.81 in the placebo group at baseline, and did not change greatly at 6 months (1.82).  In contrast, the 
ratio was 2.09 at baseline in the dalcetrapib group, and decreased to 1.89 at 6 months.  The 
difference between the change in the placebo and dalcetrapib group was not significantly different 
(P = 0.08). 
As expected, treatment with dalcetrapib decreased the activity of CETP (by 56%), and increased the 
level of HDL cholesterol by 31% at 24 months. Dalcetrapib lowered LDL cholesterol by 7%, but had 
no effect on the levels of triglycerides.  Dalcetrapib had no effect on the blood pressure.  Thus, in the 
placebo group, the mean systolic and diastolic blood pressure was 122.4/71.9 at baseline, and 
126.1/72.3 mm Hg at 24 months, and in the dalcetrapib group, 119.5/72.8 at baseline and 
119.1/69.8 mm Hg at 24 months. 
Dal-PLAQUE was not powered to detect differences in cardiovascular events with dalcetrapib, but 
Dal-PLAQUE is part of dal-HEART, which does have the power to do this.  In dal-PLAQUE, less 
cardiovascular events (coronary heart disease death, major coronary events, or stroke) occurred in 
the dalcetrapib group (3%) than in the placebo group (11%). 
4. dal-PLAQUE: discussion 
The dal-PLAQUE showed that dalcetrapib did not increase plaque progression or increase 
inflammation [10].  Indeed, dalcetrapib may decrease total vessel area and inflammation to a small 
degree [10].  The authors point out that the dal-PLAQUE data with dalcetrapib on the progression of 
atherosclerosis is consistent with the changes observed by lowering blood pressure or by treatment 
with statins [10].   
5. Expert opinion 
5.1 Trials with dalcetrapib  
In dal-PLAQUE, the subjects were all taking statins to lower their LDL cholesterol, and statins have 
previously been shown to slow or reverse atherosclerosis.  Thus, one of the important findings of 
dal-PLAQUE, is that dalcetrapib is giving benefit additional to that of the statins.  However, the 
magnitude of these changes was relatively small with dalcetrapib, and the difference in carotid 
artery total vessel area was only apparent after 24 months. 
In addition to dal-PLAQUE, there are 3 more studies underway, as part of dal-HEART.  One is dal-
PLAQUE 2, which is comparing dalcetrapib to placebo in subjects with coronary artery disease by 
measuring the atherosclerotic progression using coronary intravascular ultrasound, carotid B-mode 
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ultrasound and coronary angioplasty [17].  Another is dal-VESSEL, which is assessing the efficacy of 
dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation [18].  Finally, 
and importantly, dal-OUTCOMES will compare dalcetrapib to placebo in subjects with recent acute 
coronary syndromes for cardiovascular endpoints [19].  When dal-HEART is complete, we should 
have more definitive information about the benefit, or not, of dalcetrapib in coronary artery disease. 
5.2 Lessons from torcetrapib 
I have argued previously that torcetrapib should not have proceeded to Phase III clinical trials on the 
basis of the findings of the Phase II clinical trials with torcetrapib, which showed that it increased 
blood pressure in some subjects at risk [20].  Also, extensive preclinical testing of torcetrapib would 
have identified the increase in blood pressure with this agent, for instance, in spontaneously 
hypertensive rats, and the increase in aldosterone secretion [20].  It was only after the Phase III 
clinical trial ILLUMINATE failed, that the mechanism of the blood pressure increasing and 
aldosterone secreting effects of torcetrapib was investigated and shown to be independent of 
inhibition of CETP [21].  This meant that CETP inhibition could still be considered as a possible way to 
increase HDL cholesterol and reduce cardiovascular mortality and morbidity [21].  Also, as a 
consequence of the failure of torcetrapib, the developers of other CETP inhibitors, are checking their 
agents for blood pressure increasing effects, which should avoid a repeat of the torcetrapib debacle.   
5.3 Triglycerides 
In atherogenomic dyslipidaemia, which is often associated with diabetes or the metabolic syndrome, 
the driving force is hypertriglyceridemia [22].  The fibrates and niacin, not only increase the levels of 
HDL cholesterol, they also decrease the levels of triglycerides, which makes them useful in 
dyslipidaemia [22].  Dalcetrapib has no effect on triglycerides, but has a greater ability to increase 
HDL cholesterol than the fibrates or niacin.  It is possible that dalcetrapib will be less effective in 
reducing cardiovascular outcomes, than the agents that decrease triglycerides, in addition to 
increasing HDL cholesterol.  Thus, the effect of dalcetrapib on cardiovascular outcomes needs to be 
compared to those of the fibrates and niacin. 
5.4 The other cetrapibs  
Dalcetrapib is not the only cetrapib in clinical development; anacetrapib and evacetrapib are also 
being developed for use in subjects with or at high risk for coronary heart disease.  It has been 
recently suggested that dalcetrapib is a CETP modulator, rather than a CETP inhibitor, whereas 
torcetrapib, anacetrapib and evacetrapib are CETP inhibitors [23, 24].   Modulation of CETP with 
dalcetrapib allows the transfer of cholesteryl esters from HDL3 to HDL2 transfer, and pre-β-HDL 
formation, whereas torcetrapib and anacetrapib inhibit this [23].  It has been suggested that 
allowing this transfer, may contribute to the anti-atherogenic effect with dalcetrapib, and this may 
not occur with the inhibitors of CETP [12].  Thus, torcetrapib was shown not to have any effect on 
atheroma [6,7,8].  However, this relationship between modulation, but not inhibition, with anti-
atherogenic effects has not been firmly established to date, and requires further investigation.     
Treatment with anacetrapib 100 mg has been shown to reduce LDL cholesterol by 36%, increase HDL 
cholesterol by 139%, and to have no effect on triglycerides in 1623 subjects being treated with 
statins, and with or at high risk for coronary heart disease [25].  In this study, anacetrapib had no 
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effect on CRP, blood pressure or aldosterone levels [25].  Evacetrapib 100 mg inhibited CETP activity 
by 89%, and reduced LDL cholesterol by ~12%, increased HDL cholesterol by ~80%, , when it was 
administered in the presence of a statin, to subjects with subjects with dyslipidemia (high LDL or low 
HDL cholesterol) [26].  Also, evacetrapib had no effect on hs-CRP, blood pressure or aldosterone 
levels [26].   
In dal-PLAQUE, in the presence of statin treatment, dalcetrapib 600 mg lowered LDL cholesterol by 
7% [10], and this seems to be a point of difference between dalcetrapib or evacetrapib and 
anacetrapib, which lowers LDL cholesterol to a greater extent.  This difference may relate to 
dalcetrapib having a different mechanism of action (CETP modulator) rather than being a CETP 
inhibitor, as are the other cetrapibs.  However, further studies are needed to clarify why the effects 
on LDL cholesterol with the cetrapibs are different.  
The effects of anacetrapib or evacetrapib on the progression of atherosclerosis or cardiovascular 
endpoints have not been undertaken to date, and should be.  Trials comparing anacetrapib and 
evacetrapib with dalcetrapib, also, need to be undertaken. 
5.5 Conclusions 
In conclusion, dalcetrapib has no effect on blood pressure or aldosterone secretion and, 
consequently, should not have the adverse effects that were associated with torcetrapib.  In dal-
PLAQUE, dalcetrapib reduced the progression of atherosclerosis and may reduce the vascular 
inflammation associated with this, in subjects with, or with high risk of, coronary heart disease, who 
were already taking statins.  These results suggest that modulating CETP with dalcetrapib may be a 
beneficial mechanism in cardiovascular disease.  It is not known whether inhibiting CETP with 
anacetrapib or evacetrapib will have the same effects on atheroma or inflammation as dalcetrapib. 
The results of the dal-HEART series, which includes dal-PLAQUE 1and 2 and dal-OUTCOMES, when 
complete, will provide more definitive information about the benefit, or not, of dalcetrapib in 
coronary artery disease. 
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